Kaken Pharmaceutical Co. Overview
- Founded
-
1948
- Status
-
Public
- Employees
-
1,377
- Stock Symbol
-
4521
- Investments
-
1
- Share Price
-
$28.19
- (As of Friday Closing)
Kaken Pharmaceutical Co. General Information
Description
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
Primary Industry
Pharmaceuticals
Stock Exchange
TKS
Primary Office
- 2-28-8 Honkomagome, Bunkyo-ku
- Tokyo, 113-8650
- Japan
Kaken Pharmaceutical Co. Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $28.19 | $28.68 | $24.90 - $37.36 | $1.06B | 37.5M | 59.3K | $1.88 |
Kaken Pharmaceutical Co. Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 482,468 | 661,940 | 877,261 | 1,261,248 |
| Revenue | 604,896 | 676,801 | 707,086 | 820,675 |
| EBITDA | 122,072 | 145,821 | 197,889 | 265,919 |
| Net Income | 70,660 | 84,998 | 126,415 | 178,144 |
| Total Assets | 1,158,133 | 1,353,411 | 1,480,588 | 1,460,817 |
| Total Debt | 26,650 | 31,545 | 34,900 | 35,624 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Kaken Pharmaceutical Co. Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kaken Pharmaceutical Co. Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments betwee
Pharmaceuticals
Tokyo, Japan
1,377
As of 2022
00000000
000000
dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
000000000000000
Hyderabad, India
00000
As of 0000
00000
000000000
00000
000000
smod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
000000000000000
Lagos, Nigeria
00
As of 0000
Add Comparison
Kaken Pharmaceutical Co. Competitors (14)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aurobindo Pharma | Corporation | Hyderabad, India | 00000 | 00000 | 000000000 | 00000 |
| 000000000000000 00 | Corporation | Lagos, Nigeria | 00 | |||
| 000000000 | Corporation | Mumbai, India | 0000 | 000000000 | ||
| 000 00000000000000 | Corporation | Mumbai, India | 00000 | 000000000000 | ||
| 00. 00000'0 000000 | Corporation | Hyderabad, India | 00000 | 00000 | 00000000000 | 00000 |
Kaken Pharmaceutical Co. Patents
Kaken Pharmaceutical Co. Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3174550-A1 | Medicament containing sofpironium bromide | Pending | 03-Mar-2020 | 00000000 | |
| JP-2021138690-A | Novel pharmaceutical comprising heteroaromatic amide derivative or salt thereof | Pending | 28-Feb-2020 | ||
| EP-3972955-A1 | Crystalline form of sofpironium bromide and preparation method thereof | Pending | 23-May-2019 | 0000000000 | |
| JP-6748329-B1 | Crystal form of sofupyronium bromide and method for producing the same | Active | 23-May-2019 | 0000000000 | |
| JP-2020189839-A | Crystalline form of sofpironium bromide and preparation method thereof | Active | 23-May-2019 | C07D207/12 | 0 |
Kaken Pharmaceutical Co. Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Hiroyuki Horiuchi | Board Member & President |
Kaken Pharmaceutical Co. Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000000 00000000 | Kaken Pharmaceutical Co. | Board Member & President | 000 0000 |
| 000000 000000000 | Kaken Pharmaceutical Co. | Board Member | 000 0000 |
| 00000000 00000 | Kaken Pharmaceutical Co. | Board Member | 000 0000 |
Kaken Pharmaceutical Co. Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Kaken Pharmaceutical Co. Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 13-Dec-2021 | 0000000000 | Drug Discovery |
Kaken Pharmaceutical Co. ESG
Risk Overview
Risk Rating
Updated January, 17, 2021
34.89 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.00
Percentile
Pharmaceuticals
Subindustry
00 of 473
Rank
00.00
Percentile
